A common medication may have an unexpected effect on a serious eye condition, new research suggests.

Conference MDAngle offers personal perspectives from conference attendees, showcasing their anticipation, quick takeaways, and insights into how the presented research will affect their patients. Back ...

In its complete response letter, the FDA said Aldeyra had failed to demonstrate reproxalap’s efficacy in adequate and ...

The FDA has, for a third time, declined to approve reproxalap for the treatment of dry eye disease, according to a press ...

Sunir Garg, MD, expresses excitement about attending AAO 2025 and focuses on several topics to be discussed. These include the benefits and potential vision risks of GLP-1 inhibitors in patients with ...

The Korea Research Institute of Standards and Science (KRISS) has developed a retina-mimicking eye phantom that faithfully replicates the structural layers and microvascular network of the human ...

Shares of Aldeyra Therapeutics ALDX plunged 70.7% on Tuesday after the company announced receiving a Complete Response Letter ...

Prevent Blindness, the nation's leading patient advocacy organization dedicated to preventing blindness and preserving sight, has declared March 23-29, 2026, as its first-ever Keratoconus Week. The ...

In a genetic association study, investigators integrated data from genome-wide association studies of various disorders with retinal transcriptomic data. Findings revealed that the polygenic risk of ...

OCGN's gene-agnostic eye therapy aims to treat multiple retinal mutations, with key filings and pivotal data in 2026???2027 set to test its broad platform.

Scientists found that protein deposits in the retina create unique light patterns for different brain diseases in humans.